$0.06
(Market cap
$28 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.5
-
Debt to Equity
0
-
Book Value
$3
-
EPS
$-10.6
-
Face value
--
-
Shares outstanding
4,577,359
7 Years Aggregate
CFO
$-249.20 Mln
EBITDA
$-308.40 Mln
Net Profit
$-306.74 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NextCure Inc (NXTC)
| -57.1 | 18.9 | 0.3 | 16.3 | -30.9 | -41.5 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
NextCure Inc (NXTC)
| 53.4 | -32.2 | -19.1 | -76.5 | -45.0 | -80.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
NextCure Inc (NXTC)
|
6.1 | 27.9 | 0.0 | -42.8 | -- | -181.6 | -- | 2.3 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout NextCure Inc (NXTC)
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that... is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. Read more
-
Co-Founder, CEO, President & Director
Mr. Michael S. Richman MSBA
-
Co-Founder, CEO, President & Director
Mr. Michael S. Richman MSBA
-
Headquarters
Beltsville, MD
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for NextCure Inc (NXTC)
What is the current share price of NextCure Inc (NXTC) Today?
The share price of NextCure Inc (NXTC) is $6.09 (NASDAQ) as of 28-Aug-2026 16:00 EDT. NextCure Inc (NXTC) has given a return of -30.93% in the last 3 years.
What is the current PB & PE ratio of NextCure Inc (NXTC)?
Since, TTM earnings of NextCure Inc (NXTC) is negative, P/E ratio is not available.
The P/B ratio of NextCure Inc (NXTC) is 2.27 times as on 28-Aug-2026, a 56 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.89 |
1.42 |
2024 |
-0.03 |
0.03 |
2023 |
-0.04 |
0.02 |
2022 |
-0.05 |
0.02 |
2021 |
-0.20 |
0.06 |
What is the 52 Week High and Low of NextCure Inc (NXTC)?
The 52-week high and low of NextCure Inc (NXTC) are Rs 15.74 and Rs 1.55 as of 31-Aug-2026.
What is the market cap of NextCure Inc (NXTC)?
NextCure Inc (NXTC) has a market capitalisation of $ 28 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in NextCure Inc (NXTC)?
Before investing in NextCure Inc (NXTC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.